Skip to main content
Evidence Snapshot

MES-SA

CHEMBL614343 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:08Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614343
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats MES-SA as ChEMBL target CHEMBL614343. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
MES-SA
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614343
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why MES-SA matters

As of 2026-09-13

MES-SA is reviewed as MES-SA; the current evidence base includes 16 approved drugs, 602 compounds, and 133 assays, with lead potency reaching pChEMBL 10.9.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 602 compounds, and 133 assays for this target. The dominant activity type is IC50. CHEMBL4797377 is the current potency anchor at pChEMBL 10.9.

Use CHEMBL4797377 as the tractability anchor when discussing potency (pChEMBL 10.9).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 10.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why MES-SA matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

602
Total Compounds
133
Total Assays
16
Approved Drugs
IC50: 646.0, EC50: 13.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4797377
 10.9 EC50 —
No preferred name
CHEMBL96926
 10.6 IC50 —
No preferred name
CHEMBL4784749
 10.5 EC50 —
No preferred name
CHEMBL5182623
 10.4 IC50 —
No preferred name
CHEMBL4796838
 10.3 EC50 —

Approved Drugs

Structure Compound First Approval
MIDOSTAURIN
CHEMBL608533
 2017
PONATINIB
CHEMBL1171837
 2012
GEMCITABINE
CHEMBL888
 1996
DOCETAXEL ANHYDROUS
CHEMBL92
 1995
VINORELBINE
CHEMBL553025
 1994
PACLITAXEL
CHEMBL428647
 1992
MITOXANTRONE
CHEMBL58
 1987
ETOPOSIDE
CHEMBL44657
 1983
MITOMYCIN
CHEMBL105
 1981
DAUNORUBICIN
CHEMBL178
 1979
DOXORUBICIN
CHEMBL53463
 1974
VINCRISTINE
CHEMBL90555
 1963
COLCHICINE
CHEMBL107
 1961
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:31:08Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614343